Etoposide

證據等級: L5

預測適應症: 10 個

Etoposide: From Established Chemotherapy Use to Well-Differentiated Fetal Adenocarcinoma of the Lung

One-Sentence Summary

Etoposide (DrugBank DB00773) is a topoisomerase II inhibitor already used across multiple cytotoxic chemotherapy regimens; this evidence pack does not record its original TFDA/FDA-approved indications, as the drug is currently not marketed in Taiwan or the US under this dataset. The TxGNN model predicts it may be effective for well-differentiated fetal adenocarcinoma of the lung (the epithelial component of pulmonary blastoma), but this is currently supported by only 0 clinical trials and 1 case-report-level publication, placing this specific candidate at the earliest research stage.

Quick Overview

Item	Content
Original Indication	Not recorded in this evidence pack (no Taiwan/US license data; drug not marketed)
Predicted New Indication	Well-differentiated fetal adenocarcinoma of the lung
TxGNN Prediction Score	99.94%
Evidence Level	L4
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, this evidence pack does not include a structured original mechanism-of-action (MOA) record for etoposide (original_moa: [Data Gap]). Based on mechanistic information captured elsewhere in this same evidence pack (see the rationale for related predicted indications), etoposide is a topoisomerase II inhibitor that induces DNA double-strand breaks, producing cytotoxic effects against rapidly proliferating tumor cells — the basis for its established role in combination chemotherapy regimens (e.g., platinum-etoposide).

Well-differentiated fetal adenocarcinoma is the epithelial component of classic biphasic pulmonary blastoma, a very rare lung malignancy with a mixed epithelial/mesenchymal histology. Per the evidence pack’s rationale, “etoposide-platinum regimens have been used in case reports of related biphasic pulmonary blastoma, with a proposed mechanism of DNA damage being effective against rapidly proliferating mixed epithelial/mesenchymal tumors, though direct evidence remains extremely scarce.”

Because this disease entity is exceptionally rare, no dedicated clinical trials exist, and the mechanistic rationale — while biologically plausible — is extrapolated from a single case report rather than from disease-specific investigation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33107372	2020	Case report/Review	The Journal of International Medical Research	Case of classic biphasic pulmonary blastoma (containing well-differentiated fetal adenocarcinoma component) treated with right upper lobe resection followed by nedaplatin plus paclitaxel adjuvant chemotherapy; no standard treatment guideline exists for this rare tumor.

Cytotoxicity

Etoposide is a conventional cytotoxic chemotherapy agent (topoisomerase II inhibitor, epipodophyllotoxin class), so this section applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Topoisomerase II inhibitor / epipodophyllotoxin class)
Myelosuppression Risk	High — neutropenia is etoposide’s principal, often dose-limiting toxicity; TFDA-specific label warnings could not be retrieved in this evidence pack (see Blocking data gap below)
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential, liver and renal function, electrolytes
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Please refer to the package insert for safety information. A Blocking-severity data gap was identified: TFDA package insert warnings/contraindications for etoposide could not be located, which prevents this candidate from entering the initial safety screening stage (S1).

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for this specific indication is limited to a single case-report-level publication with zero clinical trials (Evidence Level L4). Combined with a Blocking-severity gap in TFDA safety warnings/contraindications — which by definition prevents entry into the S1 safety screening stage — this candidate cannot currently advance.

To proceed, the following is needed:

TFDA package insert data (warnings, contraindications) — currently blocking (DG001)
Structured mechanism-of-action documentation for etoposide (DG002)
Additional clinical evidence beyond a single case report, given the extreme rarity of this histologic subtype (pulmonary blastoma accounts for <0.5% of primary lung malignancies)
Taiwan/US market and licensing data, since the drug is currently not marketed in either jurisdiction per this evidence pack

Note: This evidence pack contains 9 other TxGNN-predicted indications for etoposide with markedly stronger evidence, notably primary pulmonary lymphoma and rhabdomyosarcoma (both L1, “Proceed with Guardrails,” backed by dozens of trials including Phase 3 RCTs) and Ewing sarcoma (L1, “Proceed with Guardrails”). If a viable near-term repurposing candidate is the goal, one of those ranks may warrant a separate report rather than rank 1.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.